Trial · NCT03285308
Results by group102
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 102
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Placebo | Hemoglobin (g/L): <0.9×LLN | 10 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Relamorelin 10 μg | Hemoglobin (g/L): <0.9×LLN | 4 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Placebo | Lymphocytes Absolute Cell Count (10^9/L): >1.5×ULN | 1 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Relamorelin 10 μg | Lymphocytes Absolute Cell Count (10^9/L): >1.5×ULN | 0 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Placebo | Lymphocytes Absolute Cell Count (10^9/L): <0.8×LLN | 2 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Relamorelin 10 μg | Lymphocytes Absolute Cell Count (10^9/L): <0.8×LLN | 1 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Placebo | Mean Corpuscular Volume [femtoliter (fL)]: >1.1×ULN | 2 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Relamorelin 10 μg | Mean Corpuscular Volume [femtoliter (fL)]: >1.1×ULN | 0 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Placebo | Neutrophils Absolute Cell Count (10^9/L): >1.5×ULN | 0 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Relamorelin 10 μg | Neutrophils Absolute Cell Count (10^9/L): >1.5×ULN | 1 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Placebo | Neutrophils Absolute Cell Count (10^9/L): <0.8×LLN | 2 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Relamorelin 10 μg | Neutrophils Absolute Cell Count (10^9/L): <0.8×LLN | 3 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Placebo | Platelet Count (Thrombocytes) (10^9/L): >1.5×ULN | 0 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Relamorelin 10 μg | Platelet Count (Thrombocytes) (10^9/L): >1.5×ULN | 1 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Placebo | Red Blood Cell Count (10^12/L): >1.1×ULN | 0 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Relamorelin 10 μg | Red Blood Cell Count (10^12/L): >1.1×ULN | 1 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Placebo | Red Blood Cell Count (10^12/L): <0.9×LLN | 1 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Relamorelin 10 μg | Red Blood Cell Count (10^12/L): <0.9×LLN | 1 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Placebo | White Blood Cell Count (10^9/L): >1.5×ULN | 1 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Relamorelin 10 μg | White Blood Cell Count (10^9/L): >1.5×ULN | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03285308/results?page=2